AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of the immune ...

United Kingdom-based biopharmaceutical giant AstraZeneca will add 10 to 15 new projects to the company's research and ...

Shares of AstraZeneca PLC AZN inched down 0.57% to £115.88 Monday, on what proved to be an all-around grim trading session ...

….Link noted a broadening market trend over the past couple of months, indicating that while tech has taken the lead, other ...

With the third quarter of 2024 ending, the discourse on the stock market for global equities has shifted back to interest ...

Dr Sanjeev Panchal, Country President and MD, AstraZeneca India, stated company's mission to bring innovative medicine faster ...

AstraZeneca is extending its work with Immunai through a multiyear collaboration that aims to implement its ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...

Tagrisso, which targets exon 19 deletions or exon 21 (L858R) mutations, received the approval following a priority review.

AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly ...

According to GlobalData, the US vaccination rate for seasonal influenza during the 2023-2024 season was estimated to be 47%, ...

The FDA has approved AstraZeneca's Tagrisso for treating unresectable, Stage III EGFR-mutated non-small cell lung cancer, ...